|
611
|
GSK
|
Long-acting beta2-agonists for chronic obstructive pulmonary disease
|
Cochrane Airways Group, at St George's University of London
|
Kayleigh Kew
|
Further Details
|
|
628
|
GSK
|
Predictive and Prognostic Value of Blood Cell Ratios in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib
|
Divisions of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada
|
Arnoud J. Templeton, MD
|
Further Details
|
|
631
|
GSK
|
Predictors of BPH Progression
|
Duke University
|
Dr. Stephen Freedland, MD
|
Further Details
|
|
637
|
GSK
|
Relationship of Activated Clotting Time and Bleeding Related Outcomes in the FUTURA OASIS-8 Trial
|
New York University school of Medicine, NY, NY
|
Sripal Bangalore
|
Further Details
|
|
639
|
GSK
|
Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux in Patients with Peripheral Arterial Disease
|
St Luke's-Roosevelt Hospital of the Columbia University of Physicians and Surgeons
|
Saurav Chatterjee MD
|
Further Details
|
|
645
|
GSK
|
The Influence of Age, Gender, and Race on the Effects of Combination Therapy with Carvedilol plus Lisinopril Versus Lisinopril Monotherapy for Systemic Hypertension
|
New York Medical College-Metropolitan Hospital Center, Department of Medicine, New York, NY
|
Partha Sardar
|
Further Details
|
|
646
|
GSK
|
Factors influencing immune response and patient outcomes following influenza vaccination.
|
Health Protection Research Group, University of Nottingham
|
Dr Subhadra Rajanaidu
|
Further Details
|
|
647
|
GSK
|
Assessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical Trials
|
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center
|
David M. Kent, MD, MSc
|
Further Details
|
|
651
|
GSK
|
Descriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children.
|
P95 Pharmacovigilance and Epidemiology Services
|
Thomas Verstraeten
|
Further Details
|
|
653
|
GSK
|
Functional Estimation of Interventional Effects
|
Department of Economics, Indiana University, Bloomington, Professor
Sungkyunkwan University, Professor of Economics
|
Joon Park
|
Further Details
|
|
654
|
GSK, ViiV
|
Development of Population Pharmacokinetic/Pharmacodynamic Models for Pazopanib within the EuroTARGET project (Workpackage 7)
|
Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Germany
|
Ulrich Jaehde
|
Further Details
|
|
657
|
GSK
|
Use of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trials
|
McMaster University
|
Holger Schunemann, MD, MSc, PhD
|
Further Details
|
|
668
|
GSK
|
Associations between antihypertensive drugs and patterns of blood pressure changes: a strategy to reduce the burden of anti-VEGF induced hypertension
|
Flinders University, School of Medicine, Adelaide, Australia; Southern Adelaide Health Network, Adelaide, Australia
|
Arduino A Mangoni
|
Further Details
|
|
669
|
GSK
|
A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - efficacy and adverse outcomes.
|
University of Adelaide
|
Jon Jureidini
|
Further Details
|
|
672
|
GSK
|
The Development of Toxicity Prediction Tools to Assist Oncologists in the Management of Adverse Events in Patients Receiving Treatment with Lapatinib
|
Memorial Sloan-Kettering Cancer Center
|
Dr. Mario Lacouture
|
Further Details
|
|
674
|
GSK
|
Antiepileptic drug monotherapy for epilepsy: an overview of systematic reviews andnetwork meta-analysis
|
University of Liverpool
|
Antony Marson
|
Further Details
|
|
675
|
Novartis
|
Validation study on magnitude of tumorshrinkage as a prognostic marker
|
Medical School Hannover
Hematologgy, hemostasis, oncology and stemcelltransplantation
Carl-Neuberg-Str. 1
30627 Hannover, Germany
|
Viktor Grünwald
|
Further Details
|
|
679
|
GSK
|
An Epigenetic Analysis of the ALOX5 Gene Related to the Clinical Response to Montelukast
|
University of North Carolina at Chapel Hill
Division of Pulmonary and Critical Care Medicine
130 Mason Farm Rd
Chapel Hill NC 27599-7020
|
Wayne H Anderson
|
Further Details
|
|
681
|
GSK
|
A randomized, double blind, placebo-controlled trial to evaluate the effect of rosiglitazone on metabolic markers in psoriasis patients
|
Massachusetts General Hospital
|
Alexa B. Kimball
|
Further Details
|
|
911
|
GSK
|
Outcome Measures in Systemic Lupus Erythematosus: Constructing a Meaningful Response Index from Existing Clinical Trial Data
|
Cedars-Sinai Medical Center
|
Lindsy Forbess, MD, MSc
|
Further Details
|
|
918
|
GSK
|
Outcomes after Percutaneous Coronary Intervention in Cancer patients with Acute Coronary Syndrome
|
New York Medical College, New York, NY.
|
Partha Sardar MD
|
Further Details
|
|
928
|
GSK
|
Lung function and airway inflammation response after ozone exposure 0.25ppm
|
UNC Hospitals
|
Krista Todoric, MD
|
Further Details
|
|
930
|
GSK
|
MASTERMIND: Stratification of glycaemic response the ADOPT and RECORD studies
|
NIHR Exeter Clinical Research Facility
University of Exeter Medical School
Barrack Road
Exeter
EX2 5DW
|
Professor Andrew Hattersley, M.D. FRS
|
Further Details
|
|
945
|
ViiV
|
THE CD4/CD8 RATIO AS A PREDICTOR OF NON-AIDS EVENTS DURING ANTIRRETROVIRAL THERAPY: CONFIRMATION OF ITS PREDICTIVE VALUE AND IMPACT OF MARAVIROC IN TREATMENT-EXPERIENCED PATIENTS
|
University Hospital Ramón y CAjal
|
Santiago Moreno
|
Further Details
|
|
946
|
GSK
|
Assessing models for changes in tumour size over time and how they relate to survival times.
|
Division of Mathematics, University of Dundee, Dundee, UK.
|
Raluca Eftimie
|
Further Details
|
|
951
|
GSK
|
Optimized Eltrombopag Treatment of Hepatitis C virus-related thrombocytopenia
|
The University of Jordan
|
Mohammad Saleh
|
Further Details
|
|
955
|
GSK
|
A study of subgroup identification and micro aggregation
|
National Institute of Statistical Sciences
www.niss.org
|
S. Stanley Young
|
Further Details
|
|
956
|
Roche
|
Bone Quality Project
|
University of California, San Francisco
|
Dennis M. Black
|
Further Details
|
|
976
|
GSK
|
5-alpha reductase inhibitor use and risk of lung cancer
|
Department of Internal Medicine
University of Manitoba
Department of Medical Oncology and Hematology
Cancercare Manitoba
|
Marshall Pitz
|
Further Details
|
|
977
|
GSK
|
The implication of central adjudication of COPD exacerbations by experts for treatment effect estimates and sample size calculation
|
University of Zurich
Institute of Social and Preventive Medicine
Hirschengraben 84
CH-8001 Zurich
|
Milo Puhan
|
Further Details
|
|
980
|
GSK
|
Association of leukotriene C4 synthase gene (rs730012, -444 A/C) polymorphism with response to leukotriene modifiers treatment in asthma patients
|
Institute of Epidemiology and Preventive Medicine, National Taiwan University.
Department of Family Medicine, Renai Branch, Taipei City Hospital
|
Yi-Fan Wu
|
Further Details
|
|
982
|
ViiV
|
Pharmacokinetic modeling of dolutegravir in HIV patients.
|
National Brain Research Centre,Manesar,Haryana,Gurgaon,India-122050
|
V P Subramanyam Rallabandi
|
Further Details
|
|
988
|
Roche
|
PhD Project: Bayesian Multivariate Network Meta-Analysis of Ordered Categorical Data
|
School of Health and Related Research (ScHARR) at the University of Sheffield
|
Fabrizio Messina
|
Further Details
|
|
989
|
GSK
|
Assessing at the participant level the applicability of clinical trials to a specific patient
|
Lister Hill National Center for Biomedical Communications, US National Library of Medicine, NIH
|
Amos Cahan
|
Further Details
|
|
993
|
GSK
|
A Spirometric Z-Score Based Reappraisal of the TORCH Study(GSK-SCO30003): Salmeterol and Fluticasone Propionate in COPD.
|
Yale University School of Medicine
|
Carlos A. Vaz Fragoso, MD
|
Further Details
|
|
995
|
Boehringer Ingelheim, GSK, Lilly, Roche, Takeda, UCB
|
Identifying immune modulating patterns across diseases from open clinical trial data
|
Institute for Computational Health Sciences
UCSF School of Medicine
Mission Hall - 550 16th St, San Francisco, CA 94158
email:Atul.Butte@ucsf.edu
Phone: 415-514-0511
|
|
Further Details
|
|
997
|
GSK
|
Predictors of Prostate Cancer Progression Among Men on Active Surveillance
|
Duke University
|
Stephen Freedland, MD
|
Further Details
|
|
998
|
GSK
|
Determination of minimally important difference for short form 36 and Facit Fatigue for Systemic lupus erythematosus
|
Rush University Medical Center
|
Meenakshi Jolly, MD, MSCP
|
Further Details
|
|
999
|
Boehringer Ingelheim, GSK
|
Assessing the Comparative Efficacy of Therapeutics for Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of Randomized Trials
|
Thomson Reuters
|
Kristen M Sweet
|
Further Details
|
|
1000
|
GSK
|
Review of fever and febrile convulsion rates in children after trivalent influenza vaccine.
|
National Centre for Immunisation Research and Surveillance, The Children’s Hospital at Westmead
|
Dr Jean Li-Kim-Moy, MBBS, FRACP
|
Further Details
|
|
1002
|
GSK
|
Long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease
|
Kansas City University of Medicine & Biosciences
|
Michael Sarai
|
Further Details
|
|
1013
|
GSK
|
Biopsy Avoidance in Patients At Risk For Prostate Cancer and in Patients With Low Risk Prostate Cancer: Developing Tools for Personalized Medicine
|
Princess Margaret Cancer Centre, University Health Network, Surgical Oncology, Urologist.
|
Girish Kilkarni, MD, PhD
|
Further Details
|
|
1015
|
GSK
|
Pazopanib induced liver toxicity: incidence, pathogenesis and value of liver enzymes increase as a predictor of outcome in metastatic soft tissues sarcoma patients. A retrospective multi-centric study
|
Department of Medical Oncology
University Campus Bio-Medico
Via A. Del Portillo 200, 00128
Rome, Italy
|
Bruno Vincenzi, MD, PhD
|
Further Details
|
|
1016
|
GSK
|
Statistical methods for estimating the duration of protection of malaria vaccines: secondary analysis of data from the RTSS/AS02A trial in Mozambique.
|
London School of Hygiene and Tropical Medicine
|
Paul Milligan
|
Further Details
|
|
1020
|
GSK
|
Genomic prediction tools developed using phenotypes from disease progression models
|
University of Chicago
|
Manish Sharma, MD
|
Further Details
|
|
1022
|
Novartis
|
Prediction of maximal work load (Wmax)in a bicycle test in patients with COPD.
|
Dept of Respiratory Medicine & Allergology
Lund University Hospital
22185 Lund, Sweden
|
Göran Eriksson
|
Further Details
|
|
1028
|
ViiV
|
Impact of dolutegravir on CD4+/CD8+ ratio and CD4+ percentage in HIV-infected naive patients.
|
Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAIN
|
José Ramón Blanco
|
Further Details
|
|
1053
|
GSK
|
Validation of the spirometric LMS equations in the Spanish population
|
Respiratory department, Universitary Hospital of Araba
|
Dr. Patricia Sobradillo
|
Further Details
|
|
1057
|
GSK
|
Health-related utility and disutility value in metastatic renal cell carcinoma patient treated with pazopanib
|
Department of Urology, Seoul National University Hospital, College of Medicine Seoul National University
|
Chang Wook Jeong
|
Further Details
|
|
1058
|
ViiV
|
Ritonavir-boosted protease inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimens: a systematic review and individual patient data me
|
Centre for Health & Infectious Diseases Research
Rigshospitalet, University of Copenhagen
CHIP, Department of Infectious Diseases and Rheumatology,
Section 2100, Finsencentret
Blegdamsvej 9
DK-2100 Copenhagen Ø
Denmark
|
Alvaro H Borges
|
Further Details
|
|
1071
|
Boehringer Ingelheim, GSK
|
Optimising the Analysis of vascular Prevention trials (OA-Prevention)
|
University of Nottingham
|
|
Further Details
|
|
1073
|
GSK
|
End-of-life trajectories in COPD
|
CIRO+, centre of expertise for chronic organ failure; Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands
|
Dr. Daisy J.A. Janssen
|
Further Details
|
|
1075
|
Roche
|
Efficacy and Safety of Bevacizumab in the Elderly Cancer Patients: Pooled Analysis of Ten Randomized Clinical Trials
|
Department of Biostatistics & Bioinformatics
Duke University
|
Xiaofei Wang
|
Further Details
|
|
1078
|
Lilly
|
Nocebo effects in the treatment of bipolar disorder: Results from an individual study participant level meta-analysis of the placebo arm of olanzapine clinical trials
|
University Hospital Geelong, Australia
|
Seetal Dodd
|
Further Details
|
|
1079
|
ViiV
|
The effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals.
|
Deparment of Infectious Diseases, University Hospital Ramón y Cajal, Madrid, Spaon.
|
Sergio Serrano-Villar, MD PhD
|
Further Details
|
|
1084
|
GSK
|
Studies on the relationship between corticosteroids and unfavorable medical effects. A study based on the BLISS-52 and BLISS-76 clinical trials.
|
Karolinska Institutet
Department of Medicine
Unit for Clinical Therapy Research, Inflammatory Diseases
(ClinTRID), D1:00, Karolinska University Hospital, Stockholm, Sweden
|
Ronald van Vollenhoven, MD, PhD
|
Further Details
|
|
1085
|
Roche
|
Optimized peg-interferon alpha-2a Treatment of Hepatitis C and Hepatitis B
|
The University of Jordan
|
Mohammad I Saleh, PhD
|
Further Details
|
|
1086
|
ViiV
|
Abacavir HLA-B*57:01 tolerance and genetic variation within the MHC.
|
Institute for Immunology & Infectious Diseases, Discovery Way, Murdoch, WA 6150
|
Elizabeth Phillips, MD
|
Further Details
|
|
1088
|
GSK
|
A study to identify risk factors that modify Rotarix efficacy and influence the time to rotavirus gastroenteritis among vaccinated and unvaccinated African infants.
|
University of North Carolina at Chapel Hill
|
Joann Gruber
|
Further Details
|
|
1090
|
GSK
|
Validating the test-negative case-control design for estimating rotavirus vaccine effectiveness using gold-standard randomized controlled trial data from South Africa and Malawi (Rota-037)
|
Fred Hutchinson Cancer Research Center;
Department of Biostatistics, University of Washington
|
M. Elizabeth Halloran
|
Further Details
|
|
1100
|
Boehringer Ingelheim
|
Systolic blood pressure level and risk of intracerebral hemorrhage.
|
Julius Center for Health Sciences and Primary Care
UMC Utrecht
|
Jacoba P Greving
|
Further Details
|
|
1103
|
GSK
|
A study on the possible association between antidepressant response to SSRIs and proneness for side effects
|
Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
|
Elias Eriksson, MD, PhD
|
Further Details
|
|
1108
|
GSK
|
Correlation between SF-36 PCS and MCS scores and SELENA SLEDAI activity score in SLE: a meta-anaysis.
|
Division of Clinical Immunology and Allergy, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Geneva, Switzerland
|
Chaigne Benjamin
|
Further Details
|
|
1125
|
Lilly
|
Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies.
|
Department of Psychiatry and Psychotherapy TU-München
|
Stefan Leucht
|
Further Details
|
|
1128
|
GSK
|
EuroTARGET GWAS on sunitinib pharmacogenetics in patients with metastatic renal cell carcinoma
|
Leiden University Medical Center (LUMC)
|
Prof. H.J. Guchelaar
|
Further Details
|
|
1130
|
GSK, UCB
|
Factors that determine placebo response in epilepsy trials
|
Center for Biostatistics
Department of Population Health Science and Policy
Icahn School of Medicine at Mount Sinai
One Gustave Levy Place, Box 1077
New York, NY 10029
|
Emilia Bagiella
|
Further Details
|
|
1132
|
GSK
|
Cytokine patterns in anti-viral disease vaccines: a knowledge driven approach
|
Division of Systems Medicine Chief
Department of Pediatrics
Stanford University
|
Atul J. Butte, MD, PhD
|
Further Details
|
|
1134
|
GSK
|
Incidence rate and risk factors associated with Hepatocellular carcinoma development in patients with Chronic Hpatitis C and severe thrombocytopenia: the lesson from Enable studies
|
AO FBF e Oftalmico, Milano Italy
|
Prof. Savino Bruno, MD
|
Further Details
|
|
1136
|
Takeda
|
Can Machine Learning Algorithms using General Labs Predict Clinical Remission and Mucosal Healing for Patients on Vedolizumab?
|
University of Michigan
|
Peter Higgins
|
Further Details
|
|
1137
|
GSK
|
Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease.
|
Imperial College London
|
Roy Anderson, PhD
|
Further Details
|
|
1140
|
Boehringer Ingelheim
|
Evaluation of the effect of incidental beta blocker use on clinical response to the EGFR TKI, afatinib
|
MD Anderson Cancer Center
|
John Heymach, MD, PhD
|
Further Details
|
|
1141
|
GSK
|
Multivariate methods for meta-analysis of vaccine studies with multiple correlated outcomes
|
Nuffield Department of Primary Care Health Sciences, University of Oxford
|
Merryn Voysey
|
Further Details
|
|
1142
|
Boehringer Ingelheim, GSK, UCB
|
A meta-analysis of Parkinson’s disease
|
Division of Systems Medicine
Department of Pediatrics
Stanford University
|
Atul Butte
|
Further Details
|
|
1148
|
Lilly
|
Meta-analysis of the risk of relapse in bipolar disorder
|
FIDMAG Germanes Hospitalàries & King’s College London
|
Dr. Joaquim Radua
|
Further Details
|
|
1152
|
Boehringer Ingelheim
|
Advanced analytic methods to refine phenotyping and risk prediction among patients with atrial fibrillation in the RE-LY trial
|
Yale School of Medicine
Center for Outcomes Research and Evaluation
|
Nihar Desai, MD, MPH
|
Further Details
|
|
1154
|
GSK
|
Developing New Outcome Measures for SLE by Deconvoluting Available Datasets
|
Lupus Research Institute
|
Peter E. Lipsky, MD
|
Further Details
|
|
1157
|
GSK
|
Quality-adjusted survival analysis for patients with metastatic renal cell carcinoma treated in a phase III trial of pazopanib versus sunitinib (COMPARZ trial)
|
Department of Urology, Seoul National University Hospital, College of Medicine Seoul National University
|
Chang Wook Jeong
|
Further Details
|
|
1159
|
ViiV
|
Validation of Pharmacokinetic/Viral Dynamic Modeling and Simulation using the Dolutegravir Phase IIa Dataset
|
University of Alabama at Birmingham
|
Edward P. Acosta, Pharm.D.
|
Further Details
|
|
1160
|
Boehringer Ingelheim
|
Development of a clinical decision support tool to identify patients at high risk of early or late bleeding complications from anticoagulation
|
Department of Epidemiology and Biostatistics
College of Public Health
University of Georgia
Athens, GA 30602
|
Mark H. Ebell MD, MS
|
Further Details
|
|
1161
|
Roche
|
Novel approaches to the prediction of influenza complications
|
Department of Epidemiology and Biostatistics
College of Public Health
University of Georgia
Athens, GA 30602
|
Mark H. Ebell
|
Further Details
|
|
1173
|
GSK, Lilly
|
Initial severity and antidepressant efficacy for anxiety disorders: an individual patient data meta-analysis
|
Interdisciplinary Center Psychopathology and Emotion regulation, Department of Psychiatry, University Medical Center Groningen, the Netherlands
|
Ymkje Anna de Vries
|
Further Details
|
|
1180
|
GSK
|
Evaluation of a platelet count threshold for bleeding risk in thrombocytopenic patients with chronic liver disease who undergo diagnostic and therapeutic invasive procedures.
|
Department of Internal Medicine, University of Genoa, Genoa, Italy.
|
Edoardo G. Giannini
|
Further Details
|
|
1186
|
GSK
|
Using generalized pairwise comparisons to assess the benefit/risk balance of pazopanib vs sunitinib for patients with advanced or metastatic renal cell carcinoma
|
IDDI inc
|
Marc Buyse
|
Further Details
|
|
1206
|
GSK
|
Efficacy of Belimumab on Mucocutaneous Involvement in Patients with Systemic Lupus Erythematosus (MUCOBEL)
|
Interdisciplinary Center of Clinical Trials (IZKS), University Clinic of Mainz, Germany
|
Kuhn, Annegret
|
Further Details
|
|
1224
|
GSK
|
INTERACTION BETWEEN MENINGOCOCCAL SEROGROUP B VACCINE (BEXSERO™) AND ROUTINE INFANT VACCINES ON THE RISK OF OCCURRENCE AND RECURRENCE OF ADVERSE EVENTS FOLLOWING IMMUNIZATION.
|
Institut National de Santé Publique du Québec(INSPQ)
and
Laval University
|
Gaston De Serres
|
Further Details
|
|
1234
|
Lilly
|
Predictors of Placebo Response in Pediatric Patients with Generalized Anxiety Disorder
|
University of Cincinnati
|
Jeffrey R. Strawn
|
Further Details
|
|
1236
|
GSK
|
COPERNICUS re-analysis
|
Magdi Yacoub Institute - Heart Science Centre
National Heart & Lung Institute (Myocardial Function Section)
Harefield Hospital
Hill End Road
Harefield, Middlesex, UB9 6JH
|
John Cleland
|
Further Details
|
|
1250
|
Boehringer Ingelheim, Lilly
|
The relationship of treatment effects and per capita income of study countries in duloxetine trials in the treatment of depressed patients
|
Department of Psychiatry II, Ulm University
|
Markus Koesters
|
Further Details
|
|
1256
|
GSK
|
Population mechanistic heamatotoxicity modeling of Dapsone in G6PD deficiency patients
|
Head of Department, Department of Clinical Pharmacology, Mahidol-Oxford Tropical Medicine research Unit (MORU)
|
Joel Tarning
|
Further Details
|
|
1257
|
GSK
|
An independent evaluation of the cardiovascular risk of rosiglitazone: meta-analysis of GSK’s publicly available clinical trial data
|
Yale University School of Medicine
Yale-New Haven Hospital Center for Outcomes Research and Evaluation
|
Joseph S. Ross, MD, MHS
|
Further Details
|
|
1258
|
Roche
|
Advance lung cancer inflammation index (ALI) in metastatic non-squamous lung cancer: A validation study
|
University of Texas, Houston, Texas, USA
|
Syed Hasan Raza Jafri
|
Further Details
|
|
1273
|
GSK
|
Post-hoc analysis of placebo-controlled trials in children and adolescents with depression
|
University of Gothenburg
|
Elias Eriksson
|
Further Details
|
|
1277
|
Roche
|
Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease.
|
Imperial College London
|
Roy Anderson
|
Further Details
|
|
1280
|
GSK
|
Placebo and nocebo effects in migraine Ver 2
|
University Hospitals Tuebingen
Dept. of Internal Medicine
Tuebingen, Germany
|
Paul Enck
|
Further Details
|
|
1292
|
Lilly
|
Applications of Item Response Theory to Clinical ADHD Research: Analysis of the ADHDRS-IV and Modeling Response to Treatments and Item-Level Treatment Sensitivity
|
University of California, Los Angeles
|
Alex Sturm
|
Further Details
|
|
1293
|
Roche
|
INCIDENCE OF BRAIN METASTASES IN METASTATIC BREAST CANCER PATIENTS RECEIVING PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: A METAANYLSIS OF FIVE PROSPECTIVE RANDOMIZED PHASE III TRIALS
|
Medical University of Vienna, Comprehensive Cancer Center Vienna
|
Rupert Bartsch
|
Further Details
|
|
1295
|
Boehringer Ingelheim
|
A Swapping Method Based on Covariate Classification for Average TreatmentEffect Estimation.
|
University of Maryland, Baltimore County (UMBC), Department of Mathematics and statistics
|
Dr. Bimal Sinha
|
Further Details
|
|
1307
|
Takeda
|
The Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in Patients with Chronic Kidney Disease
|
Seven Oaks General Hospital Renal Program
|
Dr. Navdeep Tangri
|
Further Details
|
|
1316
|
Boehringer Ingelheim
|
Blinding (Masking) and the Placebo Effect
|
University of Michigan Medical School
|
James Brian Byrd, MD, MS, FAHA, FACC
|
Further Details
|
|
1320
|
GSK
|
Utility of a measure of Lupus Low Disease Activity State in SLE
|
Monash Health
|
Pei Xuan Ong (Emily)
|
Further Details
|
|
1321
|
GSK
|
Bone Quality Project
|
University of California, San Francisco
|
Dennis M. Black
|
Further Details
|
|
1322
|
GSK
|
Comparative efficacy of different therapeutic approaches in the "naïve" patient with chronic obstructive pulmonary disease (COPD): analysis of patient-level data
|
None
|
Giulio Pareto
|
Further Details
|
|
1323
|
Lilly
|
Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques
|
KKT Technology pte. ltd.
|
Praveen Deorani
|
Further Details
|
|
1326
|
Lilly
|
Reliability and Validity of the Parent Rating of Evening and Morning Behavior Scale, Revised
|
SUNY Upstate Medical University
|
Steven V. Faraone, Ph.D.
|
Further Details
|
|
1331
|
Boehringer Ingelheim
|
Impact of baseline diabetes and obesity statuses on outcomes post-ischemic stroke
|
Medical University of South Carolina in Public Health Sciences
|
Colleen Bauza
|
Further Details
|
|
1335
|
GSK, UCB
|
Investigation into the natural course of epilepsy and the implications on clinical trials
|
NINDS, National Institutes of Health
|
Daniel Goldenholz
|
Further Details
|
|
1341
|
Boehringer Ingelheim
|
Vol-PACT: Improving Volumetric CT Metrics for Precision Analysis of Clinical Trial Results
|
Dana-Farber Cancer Institute
Harvard Medical School
|
Geoffrey R. Oxnard
|
Further Details
|
|
1343
|
GSK
|
Improving the Assessment of Systemic Lupus Erythematosus Disease Activity
|
University of Toronto,
University Health Network
|
Zahi Touma
|
Further Details
|
|
1373
|
GSK
|
An exploratory analysis of headache in placebo controlled trials of paroxetine for generalized anxiety disorder
|
University of Kentucky
|
Jonathan H. Smith, M.D.
|
Further Details
|
|
1374
|
GSK
|
A novel representation of vaccine efficacy trial datasets for use in computer simulation of vaccination policy
|
University of Pittsburgh
|
Michael M. Wagner
|
Further Details
|
|
1377
|
GSK
|
The association between patient outcomes under two treatments (ABOUT) in cross-over trials
|
IDDI
30 avenue provinciale
1340 Louvain-la-Neuve
Belgium
|
Marc Buyse, ScD
|
Further Details
|
|
1387
|
GSK
|
Sex-differences in immunogenicity, reactogenicity and efficacy in response to vaccines in infants and young children
|
Nuffield Department of Primary Care Health Sciences, University of Oxford
|
Merryn Voysey
|
Further Details
|
|
1393
|
Roche
|
Prognostic influence of body mass index and body weight gain in colorectal cancer patients treated with adjuvant chemotherapy: data from The AVANT study
|
Department of Internal Medicine, Seoul National University Hospital
|
Sae-Won Han
|
Further Details
|
|
1401
|
Sanofi
|
Use of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trials
|
McMaster University
|
Holger Schunemann
|
Further Details
|
|
1403
|
ViiV
|
Mathematical modeling of the HIV transmission risk during the first 24 weeks after initiation of antiretroviral therapy in naïve HIV-infected MSM
|
Hospital General Universitario Gregorio Marañón
|
Juan Berenguer
|
Further Details
|
|
1421
|
GSK
|
Cost utility analysis comparing belimumab against rituximab in systemic lupus erythematosus
|
Wingate University
|
Chris Gillette
|
Further Details
|
|
1422
|
UCB
|
Developing new outcome measures for SLE by deconvoluting available data sets
|
LRI
|
Peter E. Lipsky, MD
|
Further Details
|
|
1428
|
Boehringer Ingelheim
|
Estimating absolute treatment effect of dabigatran 110 mg bid vs. 150 mg bid (vs. warfarin) for individual patients with atrial fibrillation.
|
University Medical Center Utrecht, Utrecht, the Netherlands
|
Frank L.J. Visseren
|
Further Details
|
|
1430
|
GSK
|
Comparison of various remission criteria for SLE. A study based on the BLISS-52 and BLISS-76 clinical trials.
|
Department of Medicine, Solna
|
Ronald van Vollenhoven
|
Further Details
|
|
1433
|
Boehringer Ingelheim, Lilly, Roche
|
Identification of patient subgroups with enhanced treatment response in RCTs with time-to-event outcomes: use of counterfactual restricted survival times.
|
INSERM U1153 METHODS team, Paris, France
|
Ludovic Trinquart
|
Further Details
|
|
1450
|
Boehringer Ingelheim, Novartis
|
Understanding effectiveness of new drugs in older adults shortly after market entry.
|
Brigham and Women's Hospital and Harvard Medical School
|
Shirley V Wang
|
Further Details
|
|
1451
|
GSK
|
Assessment of bias from treatment discontinuation on mortality and exacerbations in the Towards a Revolution in COPD Health (TORCH) randomized trial
|
McGill University
|
Samy Suissa
|
Further Details
|
|
1452
|
GSK
|
A study to determine if prior rotavirus exposure modifies the effect of rotavirus vaccines given to infants in low- and middle-income African countries
|
University of North Carolina at Chapel Hill
|
Sylvia Becker-Dreps
|
Further Details
|
|
1455
|
Boehringer Ingelheim
|
Prediction of major bleeding in atrial fibrillation patients with a history of stroke or transient ischemic attack
|
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands
|
Jacoba Greving
|
Further Details
|
|
1456
|
ViiV
|
Impact of ongoing side effects on the efficacy of initial antiretroviral therapy
|
St Vincent's Hospital, Sydney
|
Andrew Carr
|
Further Details
|
|
1457
|
Lilly
|
Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies.
|
Department of Psychiatry and Psychotherapy TU-München
|
Stefan Leucht
|
Further Details
|
|
1461
|
Lilly
|
Regression discontinuity designs to evaluate real-world clinical effectiveness: a case study of drotrecogin alpha
|
Boston University
|
Allan J. Walkey
|
Further Details
|
|
1470
|
Takeda, UCB
|
The efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease
|
Gastroenterology Department, First Affiliated Hospital of Sun-YatSen University, Guangzhou, China
Director, IBD Service, Sheba Medical Center, Tel-Aviv University, Israel
|
Shomron Ben-Horin M.D.
|
Further Details
|
|
1473
|
Roche
|
Comparison of the pharmacokinetics of oral once-monthly 150mg ibandronate between ethnic Europeans and Taiwan post-menopausal osteoporotic women across two phase 1 studies
|
(1) Department of Laboratory Medicine, National Taiwan University Hospital
(2) Institute of Epidemiology and Preventive Medicine, National Taiwan University
|
Keh-Sung Tsai
|
Further Details
|
|
1475
|
Boehringer Ingelheim
|
Predicting safety and efficacy of afatinib treatment of NSCLC
|
Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, Australia
|
Assoc/Prof Michael Sorich
|
Further Details
|
|
1481
|
GSK
|
Efficacy and safety of belimumab in childhood-onset lupus
|
Columbia University Medical Center
630 168th St, Room PH 10-08
New York NY 10032
|
Dr Anca Askanase MD, MPH
|
Further Details
|
|
1514
|
Roche
|
Gain of quality-adjusted life year in patients with neovascular age-related macular degeneration after anti-VEGF treatment
|
Department of Ophthalmology,
Seoul National University Bundang Hospital
|
Park, Sang Jun
|
Further Details
|
|
1526
|
GSK
|
Assessment of correlations among all favourable and unfavourable effects for rosiglitazone/metformin, and for metformin alone, in Type 2 diabetes.
|
Department of Management
London School of Economics
Houghton Street
London WC2A 2AE
|
Lawrence D Phillips
|
Further Details
|
|
1528
|
GSK
|
A Swapping Method for Average Treatment Effect Estimation
|
Statistics, the University of Maryland at Baltimore County (UMBC)
|
Bimal Sinha
|
Further Details
|
|
1540
|
GSK
|
IMPROVING METHODS. Our research focus is to optimize the translation of clinical trial results into clinical practice.
|
Brown University
|
Dr. Issa Dahabreh
|
Further Details
|
|
1541
|
Roche
|
Item calibration of the NEI VFQ-25 to improve future comparative research using patient-reported outcome (PRO) measures.
|
Wilmer Eye Institute
Johns Hopkins School of Medicine
|
Judith E. Goldstein
|
Further Details
|
|
1542
|
Boehringer Ingelheim
|
Optimising the Analysis of vascular Prevention trials (OA-Prevention)
|
University of Nottingham
|
Philip Bath
|
Further Details
|
|
1558
|
GSK, Novartis
|
Development of historical control using placebo data from pediatric epilepsy studies
|
UCB BioSciences, Inc
8010 Arco Corporate Drive
Suite 175
Raleigh NC 27613
|
Anthony Daniels
|
Further Details
|
|
1566
|
Lilly
|
A microanalysis of symptoms and behaviors defining ADHD in adults and their response to both active medication and placebo
|
University of Utah School of Medicine Department of Psychiatry
&
Psychiatric & Behavioral Solutions LLC
|
Frederick W. Reimherr MD
|
Further Details
|
|
1567
|
Boehringer Ingelheim, Takeda
|
Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes
|
University of Exeter Medical Scool
(Honorary Consultant Physician (Diabetes) Royal Devon and Exeter Hospital)
|
Andrew Hattersley
|
Further Details
|
|
1569
|
GSK
|
Melancholic symptoms in bipolar depression and response to lamotrigine
|
Department of Psychiatry, University of Saskatchewan (U of S), Saskatchewan, Canada
|
Dr. Evyn Peters
|
Further Details
|
|
1572
|
Boehringer Ingelheim, Eisai, GSK, Lilly
|
Research to evaluate the relation of toxicity and the relative dose intensity in phase I trials beyond cycle 1 of Molecular Targeted Agents (MTAs)
|
Department of Breast and Medical Oncology
National Cancer Center Hospital, National Cancer Center, Japan
|
Kan Yonemori, MD., PhD
|
Further Details
|
|
1575
|
GSK, Lilly
|
Early improvement in individual symptoms and response to antidepressants in patients with major depressive disorder
|
Interdisciplinary Center Psychopathology and Emotion regulation, University Center of Psychiatry, University Medical Center Groningen, the Netherlands
|
Ymkje Anna de Vries
|
Further Details
|
|
1581
|
GSK
|
MASTERMIND: Assessing the cost effectiveness of a stratified approach to type 2 diabetes therapy
|
University of Bath
|
Professor Chris Jennison
|
Further Details
|
|
1587
|
Astellas
|
Sex-specific efficacy of mirabegron for overactive bladder (OAB) symptoms: individual patient data meta-analyses
|
dept. of general practice, University Medical Center Groningen, University of Groningen, the Netherlands
|
Marco H. Blanker, MD PhD
|
Further Details
|
|
1593
|
GSK
|
JANUVIA/JANUMET HTA Submission(Germany)
|
MSD Sharp & Dohme GmbH
|
Dr. Rainer Woker
|
Further Details
|
|
1595
|
Boehringer Ingelheim, GSK, Lilly, Roche
|
A Novel Approach to Developing Comprehensive Profile of Adverse Event (AE) Data from Clinical Trials
|
Cytel Statistical Software and Services Pvt. Ltd
|
Sharayu Paranjpe
|
Further Details
|
|
1599
|
Roche
|
Predictors of exposure, adverse and therapeutic effects of BRAF/MEK inhibitors in advanced melanoma.
|
Flinders University
|
Michael Sorich
|
Further Details
|
|
1600
|
Lilly
|
Item factor analysis of the SNAP-IV Parent Report Form: Generating item parameter estimates
|
University of California, Los Angeles
|
Alexandra Sturm, Ph.D.
|
Further Details
|
|
1601
|
Sanofi
|
Identification of clinical biomarkers for adjuvant chemotherapy for gastric cancer after D2 dissection by analyses of individual patents’ data from large randomized controlled trials
|
Chief of Surgery, JCHO Nihonmatsu Hospital
Research Professor, Fukushima Medical University
|
Akira Tsuburaya, MD PhD
|
Further Details
|
|
1619
|
Boehringer Ingelheim
|
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke: reanalysis of ECASS III trial to assess robustness of findings across statistical models
|
EBSCO Information Services
|
Brian S. Alper, MD, MSPH, FAAFP
|
Further Details
|
|
1622
|
ViiV
|
A systematic literature review and Individual patient-level data enhanced network meta-analysis to determine the comparative efficacy and safety of first-line HIV antiretroviral therapies
|
School of Population and Public Health
|
Steve Kanters
|
Further Details
|
|
1624
|
Lilly
|
A Meta-analysis of Tardive Dyskinesia Rates in Studies Comparing Second Generation Antipsychotics (SGAs) with each other or to First-Generation Antipsychotics (FGAs).
|
The Zucker Hillside Hospital
|
Christoph U Correll
|
Further Details
|
|
1626
|
GSK
|
Factors associated with Prostate Cancer in Prostate Needle Biopsy
|
University of Illinois at Chicago
|
Daniel M. Moreira
|
Further Details
|
|
1629
|
GSK
|
Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children
|
University of Oxford
|
Merryn Voysey
|
Further Details
|
|
1630
|
GSK
|
A framework for individualized prediction of the rate and severity of asthma exacerbations
|
Faculty of Pharmaceutical Sciences and Faculty of Medicine, University of British Columbia
|
Mohsen Sadatsafavi
|
Further Details
|
|
1633
|
ViiV
|
Comparative effect of dolutegravir and raltegravir on CD4+/CD8+ ratio, CD4%, and multiple T-cell marker recovery. SPRING-2 study.
|
Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAIN
|
Jose Ramon Blanco
|
Further Details
|
|
1637
|
Novartis
|
1618 - Optimizing Patient Reported Outcomes by Linking Study Endpoints to Real-World Benchmarks
|
University at Buffalo, SUNY
|
Dr. Jeffrey Lackner
|
Further Details
|
|
1640
|
GSK
|
Effect of Fluticasone/Salmeterol on Chronic Bronchitis Symptoms and Associated Patient Reported Outcomes: a post-hoc analysis of the TORCH trial
|
Lewis Katz School of Medicine, Temple University.
|
Victor Kim
|
Further Details
|
|
1643
|
Astellas, Lilly, Novartis, Roche
|
Development of an accurate statistical method for evaluating region-specific treatment effects in multiregional clinical trials
|
The Institute of Statistical Mathematics, Research Organization of Information and Systems, Tokyo, Japan
|
Hisashi Noma
|
Further Details
|
|
1646
|
Lilly
|
Effects of tumor burden change (response) on survival in mesothelioma
|
Mayo Clinic
|
Aaron Mansfield
|
Further Details
|
|
1654
|
GSK, Lilly
|
Placebo Response in Major Depressive Disorder.
|
University of California, Los Angeles
|
Ariana Anderson
|
Further Details
|
|
1660
|
Sanofi
|
Assessing the generalizability of all-cause mortality from the MOSAIC trial to older adults diagnosed with stage II and III colon cancer in SEER-Medicare
|
University of North Carolina at Chapel Hill, Department of Epidemiology, Gillings School of Global Public Health
|
Jennifer L. Lund
|
Further Details
|
|
1668
|
Roche
|
Quantitative Evaluation of Circadian Rhythm of Serum Glucose Level in Caucasian and Chinese Type 2 Diabetic Patients (Oct/2016)
|
Phase I Unit, Clinical Pharmacology Research Center, Peking Union Medical College Hospital
|
Pei Hu
|
Further Details
|
|
1675
|
Lilly
|
Efficacy and tolerability of SNRIs in depression.
|
Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
|
Elias Eriksson
|
Further Details
|
|
1684
|
Roche
|
ANSELMA
Antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy: an individual patient data meta-analysis
|
Gustave Roussy
|
BENJAMIN BESSE
|
Further Details
|
|
1688
|
Novartis
|
Translational data from LPT109096 to assess the impact of HER2-targeted therapies on HER-family and stem cell marker expression.
|
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
|
Denis Collins
|
Further Details
|
|
1691
|
GSK
|
Longitudinal Concurrent and Predictive Biomarkers of Clinical Disease Severity in Systemic Lupus Erythematosus in BLISS-52/BLISS-76
|
Pfizer
|
Austin Huang
|
Further Details
|
|
1692
|
Boehringer Ingelheim, GSK
|
Predictors of chronic obstructive pulmonary disease progression
|
Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba university, Chiba, Japan
|
Akihiro Hisaka
|
Further Details
|
|
1693
|
Lilly, Novartis
|
Identifying Subgroups of Response to Biologics in Psoriasis using Large-scale Patient-level Data
|
University of Manchester
|
Nophar Geifman
|
Further Details
|
|
1695
|
GSK
|
Outcome measures and baseline predictors of response to belimumab treatment.
|
Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
|
Ioannis Parodis
|
Further Details
|
|
1702
|
Roche
|
Pooled analysis of cardiac safety of T-DM1 in HER2-positive metastatic breast cancer patients
|
Institut Jules Bordet
BrEAST Data Center, Brussels Belgium
|
Evandro de Azambuja
|
Further Details
|
|
1707
|
Lilly
|
Comparative Effectiveness Analysis with Data From Randomized Clinical Trials and Observational Studies
|
The University of Hong Kong
Duke University (Adjunct)
|
Herbert Pang
|
Further Details
|
|
1721
|
Lilly, Roche
|
Improving the evaluation of new cancer therapies to expedite patient access
|
University of Adelaide
|
Professor Jonathan Karnon
|
Further Details
|
|
1726
|
Takeda, UCB
|
Association Between Obesity and Response to Biologic Therapy in Inflammatory Bowel Diseases
|
University of California San Diego
|
Siddharth Singh
|
Further Details
|
|
1731
|
GSK
|
Host characteristics impacting Rotarix immunogenicity and correlates of protection for rotavirus gastroenteritis, a multi-site pooled analysis of individual-level clinical trial data
|
Department of Epidemiology, Rollins School of Public Health, Emory University
|
Julia M. Baker
|
Further Details
|
|
1732
|
Astellas, Boehringer Ingelheim, GSK, Lilly, Novartis, Roche, Sanofi, Takeda, UCB
|
Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity.
|
University of Glasgow
|
Dr David A McAllister
|
Further Details
|
|
1733
|
Roche
|
Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment
|
Rady Faculty of Health Sciences, University of Manitoba
Children's Hospital Research Institute of Manitoba, University of Manitoba
|
Lily Lim
|
Further Details
|
|
1741
|
Lilly
|
Predictors of exposure, therapeutic and adverse effects of drugs used in the treatment of advanced breast cancer and advanced colorectal cancer.
|
Flinders University
|
Dr Ashley Mark Hopkins
|
Further Details
|
|
1749
|
GSK, Novartis, Roche
|
Bisphosphonates for the Treatment of Osteoporosis In Chronic Kidney Disease: an Individual Patient Level Systematic Review and Meta-Analyses
|
Division of Nephrology, Department of Medicine, McMaster University, Department of Health Research Methods, Evidence and Impact, affiliated to Research St. Joseph's - Hamilton
|
Dr. David Collister
|
Further Details
|
|
1752
|
GSK
|
Sex Differences in responses to umeclidinium-vilanterol treatment in COPD patients
|
Istituto superiore di sanità, Italy
|
Elisabetta Straface
|
Further Details
|
|
1758
|
Novartis
|
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease
|
Tufts Medical Center/Tufts Medical School
|
Lesley A. Inker, MD
|
Further Details
|
|
1764
|
Sanofi, Takeda
|
Personalized Medicine Model Builder and Evaluation for Diabetes Treatments
|
Queens College, CUNY and the Wharton Business School of the University of Pennsylvania
|
Adam Kapelner
|
Further Details
|
|
1779
|
GSK
|
Evaluation of the effect of inhaled corticosteroids (ICS) on blood eosinophil count (EOS) in patients with COPD
|
Division of Infection, Immunity and Respiratory Medicine
University of Manchester, UK
|
Professor Jørgen Vestbo DMSc FRCP FERS
|
Further Details
|
|
1786
|
Lilly, Novartis, UCB
|
The efficacy of biologic medications in improving depressive symptoms in patients with psoriasis and PsA – Patient-level meta-analysis of randomized clinical trials data
|
University of Toronto, Women's College Hospital, Toronto, ON, Canada
|
Dr Lihi Eder
|
Further Details
|
|
1794
|
Roche
|
A study to identify the associated factor of reported adverse event severity among HER2-positive metastatic breast cancer patient from clinical trials.
|
Centre for Investigational New Product, National Pharmaceutical Regulatory Agency (NPRA) Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia
|
OH CHEN WEI
|
Further Details
|
|
1808
|
Roche, UCB
|
Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis
|
Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal.
|
José A. P. da Silva
|
Further Details
|
|
1813
|
Takeda
|
Comparative efficacy of biologics in resolving extraintestinal manifestations of inflammatory bowel disease (IBD): a systematic review and meta-analysis
|
Mayo Clinic
|
Purna C. Kashyap, MBBS
|
Further Details
|
|
1816
|
Lilly, Roche
|
Individual patients data based meta-analysis of randomized trials assessing the interest of molecularly targeted treatments of advanced/recurrent stomach cancer:
A meta-analysis by the GASTRIC group
|
Gustave Roussy Cancer Center
Biostatistics and epidemiology dpt
INSERM CESP U1018 OncoStat
Meta-analysis platform
114 rue Ed Vaillant 94805 Villejuif cedex, France
|
Xavier Paoletti
|
Further Details
|
|
1819
|
GSK
|
INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF ANTIDEPRESSANT TRIALS FOR MAJOR DEPRESSION IN JAPAN
|
Hiroshima University
|
Shigeto Yamawaki
|
Further Details
|
|
1831
|
GSK, Novartis, Takeda
|
Statistical Methods Research to Compare the Performance of New Estimators of the Treatment Effect in Alzheimer’s Disease Randomized Trials
|
Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University
|
Michael Rosenblum
|
Further Details
|
|
1843
|
GSK
|
The genetics of glycaemic response to GLP-1 receptor agonists in Type 2 diabetes
|
University of Dundee
Dundee
DD1 9SY
|
Ewan Pearson
|
Further Details
|
|
1844
|
GSK
|
Real World Effects of Medications for Chronic Obstructive Pulmonary Disease
|
London School of Hygiene & Tropical medicine (LSHTM)
|
Dr Kevin Wing
|
Further Details
|
|
1847
|
Sanofi
|
Antiangiogenic Second line Lung cancer Meta-Analysis (ANSELMA) - A meta-analysis on antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy.
|
University Paris-Sud and Gustave Roussy, Department of Medicine
114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France
Phone: +33 (0)1 42 11 43 22
Fax: +33 (0)1 42 11 52 19
|
Benjamin Besse
|
Further Details
|
|
1851
|
Roche
|
Validation of a Novel Outcome Instrument for SLE Clinical Trials Using Phase II Rontalizumab Study Data Set.
|
UCSD School of Medicine
|
Kenneth Kalunian
|
Further Details
|
|
1857
|
GSK, Novartis
|
Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysis
|
Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
|
Andrea C. Tricco
|
Further Details
|
|
1880
|
Boehringer Ingelheim, Eisai, Lilly, Roche, Sanofi
|
Improving the evaluation of new cancer therapies to expedite patient access
|
University of Adelaide
|
Professor Jonathan Karnon
|
Further Details
|
|
1907
|
GSK
|
Critical characterization of the impact of clinical-pathological tumoral features on recurrence risk dynamics of NSCLS.
|
European institute of Oncology , Milan
|
Tommaso De Pas
|
Further Details
|
|
1911
|
Boehringer Ingelheim, Daiichi Sankyo
|
Lower incidence of atrial fibrillation in NOAC treated patients without prior AF
|
Department of Cardiology, Maastricht University Medical Centre, Maastricht, the Netherlands
|
Ömer Erküner
|
Further Details
|
|
1925
|
GSK
|
EstablishINg the best STEp-up treatments for children with uncontrolled asthma despite Inhaled corticosteroids (EINSTEIN): A systematic review, network meta-analysis and cost effectiveness analysis
|
University of Liverpool
|
Catrin Tudur Smith
|
Further Details
|
|
1928
|
GSK
|
The development of a disease progression model to describe the long-term effects of anti-diabetic medications on Hemoglobin A1C
|
The University of Jordan
|
Mohammad Saleh
|
Further Details
|
|
1933
|
Novartis
|
Benefit-harm assessment of Fingolimod: a novel methodology to inform patients with MS, industry, guideline developers and regulatory agencies on the balance of benefits and harms
|
University of Zurich
Institute of Social and Preventive Medicine
Hirschengraben 84
CH-8001 Zurich
|
Alessandra Spanu
|
Further Details
|
|
1934
|
GSK
|
Using zanamivir trial data to evaluate baseline characteristics and disease progression by various subgroups to inform clinical development of novel therapies in hospitalized patients with influenza
|
Genentech, Inc., A member of the Roche Group
|
Lesley Butler
|
Further Details
|
|
1955
|
Boehringer Ingelheim
|
Development and validation of a model to predict absolute vascular risk reduction due to intensive blood-pressure targets in individual patients at baseline and after three months
|
University Medical Center Utrecht, Utrecht, the Netherlands
|
F.L.J. Visseren
|
Further Details
|
|
1973
|
Roche
|
The Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes
|
Investigational Drug Branch Cancer Therapy Evaluation Program Division of Cancer Treatment and Diagnosis National Cancer Institute
|
Elad Sharon
|
Further Details
|
|
1996
|
Sanofi
|
Statistical Methods for Causal Inference Adjusting for Adherence
|
Southern Methodist University Department of Statistics
University of Texas Southwestern Medical Center Department of Clinical Sciences
|
Daniel Heitjan
|
Further Details
|
|
2029
|
GSK
|
Matching the Right Antidepressants with the Right Patients: Using Artificial Intelligence to Personalize the Treatment of Depression
|
Douglas Mental Health University Institute McGill University
|
Gustavo Turecki
|
Further Details
|
|
2033
|
Boehringer Ingelheim
|
Applying machine learning tools to personalize dabigatran treatment decisions
|
Stanford University
|
Sanjay Basu
|
Further Details
|
|
2036
|
Boehringer Ingelheim
|
Prediction of bleeding events in patients with non-valvular atrial fibrillation - validation of the VTE-BLEED score
|
Leiden University Medical Centre, Leiden, Netherlands
|
Menno V Huisman
|
Further Details
|
|
2056
|
Lilly
|
Breakthrough on Antipsychotic Maintenance Medication: An Individual Participant Data Meta-Analysis.
|
The Zucker Hillside Hospital,
The Feinstein Institute of Biomedical Research
Northwell Health
|
Jose M Rubio M.D.
|
Further Details
|
|
2069
|
Lilly
|
Estimating the impact of different approaches to the analysis of time-to-event and longitudinal data on modelled cost-effectiveness.
|
School of Health and Related Research (ScHARR), The University of Sheffield
|
Ben Kearns
|
Further Details
|
|
2074
|
Roche
|
Association between pertuzumab induced diarrhea and cutaneous rash and survival outcomes in patients with HER2-positive metastatic breast cancer enrolled in the CLEOPATRA trial
|
Institut Jules Bordet
|
Evandro de Azambuja
|
Further Details
|
|
2084
|
GSK
|
Relationship between plasma levels of a1-Antitrypsin levels and the severity of airflow limitation
|
Pneumology Department. Hospital Universitari Vall d'Hebron. Barcelona, Spain
|
Marc Miravitlles
|
Further Details
|
|
2085
|
GSK
|
Identify Systemic Lupus Erythematosus (SLE) Patients Treated with Belimumab with Reduced Severe and Severe/Moderate Flares: A Post-hoc Trial Analysis
|
Johns Hopkins University
Bloomberg School of Public Health
Department of Health Policy and Management
Center for Drug Safety and Effectiveness
Center for Population Health IT
|
Hongjun Kan
|
Further Details
|
|
2087
|
Lilly
|
Effectiveness of rhGH in Children with GHD in GeNeSIS (NCT01088412) - revised
|
Founder and Chief Scientific Officer, Ammonett Pharma
Retired from University of Virginia after serving on faculty for 40 years as a clinical investigator, Division Chief Endocrinology and Metabolism, Chairman of the Department of Medicine
|
Michael O. Thorner
|
Further Details
|
|
2099
|
Boehringer Ingelheim
|
Blood pressure variability in PRoFESS and development of incident stroke
|
University of Utah, Department of Neurology
|
Adam de Havenon
|
Further Details
|
|
2100
|
GSK
|
Review of post-vaccination fever and antipyretic use and their relation to vaccine immunogenicity after quadrivalent influenza vaccine in children.
|
National Centre for Immunisation Research and Surveillance, The Children's Hospital at Westmead
|
Dr Jean Li-Kim-Moy
|
Further Details
|
|
2110
|
Lilly
|
Effects of tumor burden change (response) on survival in mesothelioma
|
Mayo Clinic
|
Aaron Mansfield
|
Further Details
|
|
5453
|
Roche
|
Evaluation of Postmastectomy Radiotherapy in Women with HER-2 positive Breast Cancer
|
American University of Beirut, Medical Center
|
Youssef Zeidan
|
Further Details
|
|
5459
|
GSK
|
Placebo Effects in Asthma Randomized Clinical Trials: Their Magnitudes, Causes and Potential for Improving Care
|
The Ottawa Hospital Research Institute, University of Ottawa
|
Shawn D. Aaron
|
Further Details
|
|
5460
|
GSK
|
The evaluation of hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection against laboratory-confirmed influenza infections
|
School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong.
|
Prof Benjamin J Cowling
|
Further Details
|
|
5471
|
GSK
|
Evaluating predictors of antidepressant response or remission in children and adolescents with depression
|
University of Maryland Baltimore, School of Pharmacy, Pharmaceutical Health Services Research Department
|
O'Mareen Spence, MPH
|
Further Details
|
|
5494
|
Sanofi
|
Improving Colon Cancer Therapy Decisions by Extending Trial Representation
|
Department of Epidemiology, University of North Carolina at Chapel Hill
|
Jennifer Lund
|
Further Details
|
|
5495
|
Boehringer Ingelheim
|
Applying clinical trial results in clinical decision-making: Impact of a patien's baseline risk on the relative effect of an intervention strategy.
|
University Medical Center Utrecht, Utrecht, the Netherlands
|
Frank L.J. Visseren
|
Further Details
|
|
5499
|
Roche
|
Incorporating biomarkers into survival models to predict patient
|
Rutgers University
|
Dr. Luigi Brunetti, PharmD, MPH
|
Further Details
|
|
5501
|
Roche
|
Efficacy and Tolerability of Trastuzumab-Emtansine in Elderly Patients with Advanced Breast Cancer; A Combined Analysis
|
Institut Jules Bordet
|
Noam Pondé
|
Further Details
|
|
5502
|
Lilly
|
Health Determinants of the quality of life among children with ADHD: a structural equation modelling approach
|
National Research Council, Neuroscience Institute, Padova, Italy
|
Nadia Minicuci
|
Further Details
|
|
5504
|
Boehringer Ingelheim
|
Estimating Oral Anticoagulant Comparative Effectiveness in the Setting of Effect Heterogeneity: Comparing Clinical Trial Transport and Observational Epidemiologic Methods
|
University of North Carolina at Chapel Hill
|
Michael Webster-Clark
|
Further Details
|
|
5505
|
Boehringer Ingelheim, Lilly
|
A Data-Driven Statistical/Machine Learning Analysis for Extracting Clinically Actionable Predictions of Antidepressant Treatment Outcomes with Individual Depressive Symptoms
|
Mayo Clinic, Dept. of Psychiatry and Psychology
|
William V. Bobo
|
Further Details
|
|
5506
|
Lilly
|
Development of a limited sampling strategy for pharmacokinetic studies with pemetrexed.
|
Radboud University Medical Center
|
Rob ter Heine
|
Further Details
|
|
5509
|
Boehringer Ingelheim
|
Statistical methodology for the analysis of incomplete data in non-inferiority clinical trials.
|
University of Connecticut, Department of Statistics, CT, USA
|
Yulia Sidi
|
Further Details
|
|
5513
|
Lilly, Novartis
|
Association of sunlight intensity with Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms and interactions with pharmacological treatment: A cross-sectional approach.
|
Research Institute Brainclinics, Nijmegen, The Netherlands Utrecht University, Dept. of Experimental Psychology, Utrecht, The Netherlands
|
Martijn Arns
|
Further Details
|
|
5515
|
GSK
|
Impact of HPV16/18 vaccine on HPV genotype infection and cervical precancerous lesions: an implication for cervical cancer screening strategy
|
National Cancer Center & Cancer Hospital, Chinese Academy of Medical Sciences
|
Fanghui Zhao
|
Further Details
|
|
5521
|
GSK
|
Impact of HPV vaccination in preventing subsequent infection and disease after excision treatment
|
National Cancer Center & Cancer Hospital, Chinese Academy of Medical Sciences
|
Fanghui Zhao
|
Further Details
|
|
5525
|
GSK
|
Novel approaches for the analysis of SLE clinical trials
|
Albert Einstein College of Medicine
|
Mimi Kim
|
Further Details
|
|
5528
|
Boehringer Ingelheim
|
Spirometric Z-Score Reappraisal of the UPLIFT Trial: A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
|
Yale University School of Medicine
|
Carlos A. Vaz Fragoso, MD
|
Further Details
|
|
5548
|
Boehringer Ingelheim, Lilly, Roche
|
Predictors of exposure, therapeutic and adverse effects of targeted therapeutics used in the treatment of lung cancer.
|
Flinders University
|
Ashley Hopkins
|
Further Details
|
|
5549
|
Boehringer Ingelheim
|
Model-based meta-analysis of anticoagulant therapy based on individual patient data
|
Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan
|
Hisaka Akihiro
|
Further Details
|
|
5565
|
Eisai
|
Predictors of exposure, therapeutic and adverse effects of lenvatinib used in the treatment of advanced thyroid cancer.
|
Flinders University
|
Ashley Hopkins
|
Further Details
|
|
5567
|
Lilly
|
PROCLAIM trial secondary analysis: Request for data to determine pre- and mid-treatment neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios and lymphocyte nadir values to analyze if they are predictive of survival outcome.
|
University Hospitals Siedman Cancer Center, Case Western Reserve University, Cleveland, OH
|
Tithi Biswas
|
Further Details
|
|
5602
|
Roche
|
Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers.
|
Flinders University
|
Ashley Hopkins
|
Further Details
|
|
5625
|
Roche
|
Investigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment response
|
Stanford University
|
Matthew Baker
|
Further Details
|
|
5642
|
GSK
|
FEV1 decline across BMI gradient in COPD patients who were part of large randomized controlled trial over at least 3 years.
|
Centre for Heart Lung Innovation, St Paul's Hospital and Division of Respiratory Medicine, University of British Columbia,Vancouver, BC V6Z 1Y6, Canada
|
Don D Sin
|
Further Details
|
|
5644
|
GSK, Lilly, Sunovion
|
Factor analysis using the Generalisability Theory of PANSS data from clinical trials in schizophrenia and bipolar disorder
|
University Hospital Geelong, Barwon Health, Geelong, Australia
|
Seetal Dodd
|
Further Details
|
|
5652
|
UCB
|
Efficacy of Crohn's Disease Treatment Stratified by Disease Phenotype
|
University of California - San Francisco
|
Vivek Rudrapatna
|
Further Details
|
|
5655
|
Astellas, Bayer, Boehringer Ingelheim, GSK, Lilly, Roche, Sanofi, Takeda, ViiV
|
Prediction of recruitment in randomized clinical trials (RECRUIT-IT)
|
Department of Medical Oncology & Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
|
Kasenda Benjamin
|
Further Details
|
|
5658
|
GSK
|
Does Shingrix vaccination reduces the risk of stroke?
|
University of Antwerp & Antwerp University Hospital
|
Benson Ogunjimi
|
Further Details
|
|
5742
|
Boehringer Ingelheim, GSK, Novartis
|
Comparison of the effects of dual and single bronchodilators in COPD patients relocated from group D to group B by the revised 2017 GOLD classification: a post-hoc pooled analysis of global RCTs
|
Professor, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea Head, the Department of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, South Korea
|
Yeon-Mok Oh
|
Further Details
|
|
5758
|
Roche
|
Predicting the real world effectiveness and safety of medical interventions
|
Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
|
Orestis Efthimiou
|
Further Details
|
|
5769
|
GSK
|
The risk of recurrent Plasmodium vivax malaria and haematological effect of treatment with or without primaquine: a systematic review and individual patient data meta-analysis
|
Menzies School of Health Research, Darwin, Australia WorldWide Antimalarial Resistance Network (WWARN), University of Oxford, UK
|
Rob Commons
|
Further Details
|
|
5775
|
Roche
|
Early identification of immunotherapy response based on computational models
|
Applied Tumor Immunity (D120) National Center for Tumor Diseases (NCT) German Cancer Research Center (DKFZ) Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany Gastroenterology and Gastrointestinal Oncology University Hospital RWTH Aachen Pauwelsstraße 30, D-52074 Aachen, Germany
|
Jakob Nikolas Kather
|
Further Details
|
|
5783
|
Sanofi
|
Co Medication (aspirin, statins and metformin) analysis in patients with metastatic Castration Resistant Prostate Cancer treated with Chemotherapy.
|
VALL D HEBRON INSTITUTE OF ONCOLOGY VALL D'HEBRON UNIVERSITY HOSPITAL Passeig Vall d'Hebron 119-129 08035 BARCELONA
|
Joan CARLES
|
Further Details
|
|
5791
|
Novartis
|
Trends of CRT therapy in heart failure patients with reduced ejection fraction on LCZ696 versus Enalapril
|
University of Miami
|
Abdullah Sarkar MD
|
Further Details
|
|
5793
|
Astellas, UCB
|
Predictors of exposure, therapeutic and adverse effects of certolizumab pegol used in the treatment of rheumatoid arthritis.
|
Australian Center for Pharmacometrics, School of Pharmacy and Medical Sciences, University of South Australia
|
Ahmad Y Abuhelwa
|
Further Details
|
|
5796
|
GSK
|
Symptom level analysis of recovery during antidepressant treatment
|
Department of Psychology and Logopedics, Medical Faculty, University of Helsinki, Helsinki, Finland
|
Markus Jokela
|
Further Details
|
|
5805
|
GSK
|
Choosing the Right Antidepressant for Depression: Individual Patient Data Network Meta-Analysis
|
Department of Psychiatry, University of Oxford 	 Oxford Health NHS Foundation Trust
|
Professor Andrea Cipriani
|
Further Details
|
|
5806
|
GSK
|
Melancholic depression and response to lamotrigine for the treatment of acute bipolar depression: a pooled analysis of five randomized controlled trials
|
Department of Psychiatry, College of Medicine, University of Saskatchewan
|
Dr. Evyn Peters
|
Further Details
|
|
5807
|
Lilly, Novartis, Roche
|
Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of breast cancer.
|
Flinders University
|
Ashley Hopkins
|
Further Details
|
|
5808
|
Roche
|
Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
|
Leiden University Medical Center
|
Diane van der Woude
|
Further Details
|
|
5809
|
Roche
|
Effectiveness of anti HER2 blockade according to host immune status
|
Gangnam Severance Hospital Department of Surgery
|
Joon Jeong
|
Further Details
|
|
5814
|
UCB
|
Calculating the Ankylosing Spondylitis Disease Activity Score (ASDAS) in radiographic and non-radiographic axial spondyloarthritis when Patient Global Assessment (PGA) is not available
|
Leiden University Medical Center (LUMC)
|
Désirée van der Heijde
|
Further Details
|
|
5815
|
GSK
|
Examining statistical methods to allow comprehensive evaluation and presentation of adverse event data in randomised controlled trials
|
Imperial College London
|
Rachel Phillips
|
Further Details
|
|
5819
|
GSK
|
The immunogenicity and efficacy of pneumococcal vaccines: a systematic review and network meta-analysis of individual participant data
|
University of Oxford
|
Merryn Voysey
|
Further Details
|
|
5835
|
GSK
|
Combined effect of belimumab and hydroxychloroquine treatment : results from the phase 3 belimumab clinical trials in patients with SLE
|
Center of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
|
Savino Sciascia
|
Further Details
|
|
5836
|
Roche
|
Exploring possibilities to improve the risk:benefit balance through anlaysis of the ocrelizumab phase II extension study
|
Blizard Institute Barts and the London School of Medicine and Dentistry Queen Mary University of London 4 Newark Street London EC1 2AT
|
David Baker/Klaus Schmierer
|
Further Details
|
|
5847
|
GSK
|
Effectivity of Belimumab in arthritic and hematologic SLE manifestations
|
Dep. of Internal Medicine III Carl Gustav Carus Medical Center University of Dresden Germany
|
Nicolai Leuchten
|
Further Details
|
|
5851
|
Novartis
|
Statistical Methods for Analyzing KCCQ in Heart Failure Trials
|
Department of Mathematics & Statistics University of Maryland Baltimore County Baltimore, MD
|
DoHwan Park, Ph.D.
|
Further Details
|
|
5855
|
GSK
|
A clinical practice for detecting the phases of Herpes Zoster.
|
* Athens University of Economics and Business, Department of Statistics (www.stat-athens.aueb.gr ) * Frontier Science Foundation Hellas (www.frontier-science.gr )
|
Dimitris Karlis
|
Further Details
|
|
5862
|
GSK
|
Impact of belimumab on antiphospholipid antibodies in patients with Systemic Lupus Erythematosus
|
1st Department of Propaedeutic and Internal Medicine, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Greece
|
Katerina Chatzidionysiou
|
Further Details
|
|
5865
|
GSK
|
Hospitalized influenza clinical studies: benchmarking and refinement of clinical endpoints
|
Biomedical Advanced Research and Development Authority (BARDA) Office of the Assistant Secretary for Preparedness and Response (ASPR) Department of Health and Human Services (HHS)
|
Kimberly Armstrong
|
Further Details
|
|
5880
|
Roche
|
Assessing immune system correlates to individual tumour size dynamics
|
University of Manchester, Manchester, UK
|
Dr Hitesh Mistry
|
Further Details
|
|
5881
|
Novartis
|
Relationship between outcomes and systolic blood pressure reduction during the first 24 h in acute heart failure syndrome: an exploratory analysis of the Relax-AHF-studies
|
The University of Copenhagen, and the Department of Cardiology, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark
|
Olav Wendelboe Nielsen
|
Further Details
|
|
5886
|
GSK
|
Efficacy of belimumab in patients with active systemic lupus erythematosus and concomitant antiphospholipid syndrome
|
Istituto Auxologico Italiano, IRCCS, Laboratory of Immunorheumatology, Milan, Italy.
|
Pier Luigi Meroni
|
Further Details
|
|
5895
|
ViiV
|
Pharmacogenetics of Interaction between Efavirenz and Dolutegravir
|
Vanderbilt University Medical Center Nashville, Tennessee
|
David W. Haas, MD
|
Further Details
|
|
5904
|
Lilly, Roche
|
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer
|
Iowa State University
|
Benjamin K Schneider
|
Further Details
|
|
5906
|
UCB
|
Modelling seizure rates rather than time to an event within clinical trials of antiepileptic drugs
|
University of Liverpool
|
Laura Bonnett
|
Further Details
|
|
5915
|
GSK
|
SLE clinical and laboratory profiling to indentify best response to belimumab: results from the phase III belimumab clinical trials
|
Center of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. MD, Consultant in Clinical Immunology
|
Savino Sciascia
|
Further Details
|
|
5936
|
Takeda, UCB
|
The impact of biological interventions on health-related quality of life in adults with Crohn's disease
|
UHC rijeka, krešimirova 42, 51000 Rijeka, Croatia
|
Mirjana Stanic Benic
|
Further Details
|
|
5937
|
Roche
|
Predictors of exposure, therapeutic and adverse effects of tocilizumab used in the treatment of rheumatoid arthritis.
|
University of South Australia
|
Ahmad Y Abuhelwa
|
Further Details
|
|
5951
|
Lilly
|
Alternative Data Presentation For Treatment Outcomes in Psoriasis
|
University of Alberta, Faculty of Medicine & Dentistry, Division of Dermatology, Canada
|
Robert Gniadeki
|
Further Details
|
|
5979
|
Lilly
|
Predictors of exposure, therapeutic and adverse effects of baricitinib used in the treatment of rheumatoid arthritis.
|
Australian Center for Pharmacometrics, School of Pharmacy and Medical Sciences, University of South Australia
|
Ahmad Y Abuhelwa
|
Further Details
|
|
5981
|
Roche
|
Multi-state models for the analysis of survival data in radiation therapy.
|
Department of Radiotherapy, Paoli Calmettes Institute, Marseille, France.
|
Pierre Annede
|
Further Details
|
|
5988
|
Lilly, Novartis, Roche
|
Pattern Extraction and Patient-Level Prediction of Adverse Events Using Meta-Analysis and Matrix Decomposition
|
Tokyo University of Science
|
Kentaro Matsuura
|
Further Details
|
|
5995
|
Novartis
|
An investigation of clinical outcome measures in PPMS to inform the design of investigator initiated clinical trials.
|
University of Calgary, Calgary, Alberta, Canada
|
Marcus Koch MD PhD
|
Further Details
|
|
6001
|
Lilly
|
Can I use machine learning to build a prediction model of individual patient outcome in first episode psychosis?
|
Institute of Mental Health & Wellbeing, University of Glasgow Honorary Specialty Registrar General Adult Psychiatry, NHS Greater Glasgow & Clyde
|
Dr Samuel Leighton
|
Further Details
|
|
6009
|
GSK
|
Examining Immune Setpoints in Children and Adults Who Received Multivalent Hepatitis B Vaccines
|
J. Craig Venter Institute (JCVI)
|
Yun Zhang
|
Further Details
|
|
6042
|
Eisai, GSK, Sanofi
|
An investigation into unblinded sample size re-estimation methodology in clinical trials
|
The University of Sheffield
|
Julia Edwards
|
Further Details
|
|
6066
|
Novartis
|
Evaluating the role of Clinical Study Reports, as unpublished sources of evidence for the use of sacubitril/valsartan in adults and its impact on evidence synthesis.
|
Department of General Practice and HRB Centre for Primary Care Research
|
Dr David Byrne
|
Further Details
|
|
6078
|
Novartis, Roche
|
Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients
|
American University of Beirut, Medical Center
|
Youssef Zeidan
|
Further Details
|
|
6080
|
Roche
|
Exploratory Analysis of CRANE Influenza Study to Assess Impact of MHAA4549A among Subgroups Classified by Influenza Severity
|
Veristat
|
Robin Bliss
|
Further Details
|
|
7080
|
Roche, Sanofi
|
The clinical outcome based on the treatment course factors in CLASSIC trial.
|
Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan
|
Hisaka Akihiro
|
Further Details
|
|
7082
|
Roche
|
Evaluation of Radiotherapy Boost in Women with HER-2 positive Breast Cancer.
|
Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
|
Youssef Zeidan
|
Further Details
|
|
8102
|
GSK
|
Open Label Extension Analysis - Exploring Self-Controlled Case Series Methodology
|
London School of Hygiene and Tropical Medicine
|
Ian Douglas
|
Further Details
|
|
9115
|
GSK
|
inhaled STerOids for the Prevention of Lung Cancer. (STOP Lung Cancer)
|
Clínica Universidad de Navarra
|
Luis Seijo
|
Further Details
|
|
9131
|
GSK
|
Validation of the diabetes microsimulation model in the HARMONY trial
|
University of Florida College of Pharmacy
|
Hui Shao
|
Further Details
|
|
9134
|
ViiV
|
Population pharmacokinetic analysis of interaction between dolutegravir and rifampin
|
Department of Medicine University of Cape Town Health Sciences Faculty
|
Gary Maartens
|
Further Details
|
|
9136
|
Novartis
|
Association Between Blood Pressure and Cardiovascular Outcomes in Liver Transplant Recipients.
|
Northwestern University Feinberg School of Medicine
|
Lisa B VanWagner MD MSc FAST FAHA
|
Further Details
|
|
9140
|
Eisai
|
INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF DONEPEZIL FOR ALZHEIMER'S DISEASE
|
Kyoto University Graduate School of Medicine / School of Public health
|
Toshi A. Furukawa
|
Further Details
|
|
10141
|
GSK
|
Impact of rotavirus genotype and local rotavirus gastroenteritis incidence on Rotarix vaccine efficacy estimates: a multi-site pooled analysis of individual-level clinical trial data
|
Department of Epidemiology, Rollins School of Public Health, Emory University
|
Avnika B. Amin
|
Further Details
|
|
10189
|
Roche
|
Evaluation of Radiotherapy in Triple Negative Breast Cancer: Analysis of the BEATRICE trial
|
American University of Beirut, Medical Center
|
Youssef Zeidan
|
Further Details
|
|
10195
|
GSK
|
Relationship Between Baseline Blood Electrolyte Levels and Risk of Asthma Exacerbation
|
Gossamer Bio
|
Greg Opitek
|
Further Details
|
|
10204
|
Novartis
|
Validity of Renal Transplant Outcomes in the Australian and New Zealand Dialysis and Transplant Registry: Comparison with Clinical Trials Data
|
Employer: Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia Research Affiliation: University of Sydney, Sydney, NSW, Australia
|
Tracey Ying
|
Further Details
|
|
11223
|
Novartis, Roche, Sanofi
|
Individualizing Treatment Decisions for Adult Relapsing-Remitting Multiple Sclerosis Patients Using Statistical Learning Methods
|
Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
|
Prof Dr Ulrike Held
|
Further Details
|
|
11229
|
GSK
|
Exploration of the Hospital Recovery Scale as an endpoint to assess clinical improvement in hospitalized influenza patients
|
Janssen R&D Belgium
|
Wilbert van Duijnhoven
|
Further Details
|
|
11230
|
Roche, Sanofi
|
A systematic review of prognostic biomarkers in idiopathic pulmonary fibrosis
|
University of Nottingham
|
Prof Gisli Jenkins
|
Further Details
|
|
11236
|
GSK
|
Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) validation: post-hoc analysis of the BLISS-52 and BLISS-76 phase III trials.
|
Professor of Rheumatology and Head of the CHUC Lupus Clinic, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra. Coimbra, Portugal Professor of Rheumatology at Faculty of Health Sciences, University of Beira Interior. Covilhã, Portugal
|
Luís Inês
|
Further Details
|
|
11254
|
GSK
|
Evaluation of the pharmacokinetics of valacyclovir in subjects 1 month of age or older in order to assist in the design of a safer, more beneficial study of its pharmacokinetics in neonates under 2 weeks of age.
|
University of Alabama at Birmingham
|
David Kimberlin, MD
|
Further Details
|
|
11278
|
GSK, Sanofi
|
Exploration of regional heterogeneity in trials assessing the efficacy of recent non-insulin glucose lowering drugs on cardiovascular outcomes
|
Pharmacologie clinique, Université Grenoble Alpes Centre d'Investigation Clinique, Inserm CIC1406 CHU Grenoble Alpes Laboratoire HP2, Inserm UMR 1042 Tel: 06 73 98 36 37 mroustit@chu-grenoble.fr
|
ROUSTIT MATTHIEU
|
Further Details
|
|
11280
|
GSK
|
Antibody response to primary and booster immunization in infants born to mothers immunized with pertussis-containing vaccines during pregnancy versus unimmunized women: a systematic review and meta-analysis
|
University of British Columbia, Canada
|
Dr. Manish Sadarangani
|
Further Details
|
|
11283
|
GSK
|
Association between Vaginal Infection and Cervical Non-HPV16/18 Infection in Women after Bivalent HPV Vaccination
|
Cancer Hospital, Chinese Academy of Medical Sciences
|
Fanghui Zhao
|
Further Details
|
|
11288
|
Novartis
|
Clinical Trial Diversity for Common Dermatologic Diseases: A Systematic Review
|
University of Pennsylvania
|
Junko Takeshita
|
Further Details
|
|
11298
|
GSK
|
Development of personalised predictive models for the evolution of atopic dermatitis severity in response to treatment
|
Department of Bioengineering, Imperial College London
|
Reiko Tanaka
|
Further Details
|
|
11302
|
GSK
|
Assessment of the prognostic impact of including standard serological markers in the definitions of remission and low lupus disease activity in patients with SLE
|
University of Crete Medical School; University Hospital of Heraklion, Greece
|
George Bertsias
|
Further Details
|
|
11340
|
GSK
|
Towards precision medicine in Chronic Obstructive Pulmonary Diseases: predicting individual treatment response and general outcomes in SUMMIT
|
University Hospitals Leuven Department of Respiratory Diseases Research Laboratory BREATHE, Department CHROMETA, KU Leuven Herestraat 49 3000 Leuven Belgium
|
Wim Janssens
|
Further Details
|
|
11347
|
GSK
|
Estimation of primary, secondary and composite effects of the RTSS/AS01 vaccine
|
London School of Hygiene&Tropical Medicine
|
Paul Milligan
|
Further Details
|
|
11384
|
GSK
|
Human papillomavirus(HPV) vaccine efficacy and immunogenicity in women with existing HPV infections
|
National Cancer Center & Cancer Hospital,Chinese Academy of Medical Sciences
|
Fanghui Zhao
|
Further Details
|
|
11435
|
GSK
|
Natural history of human papillomavirus and associated lesions in healthy Chinese women
|
National Cancer Center & Cancer Hospital,Chinese Academy of Medical Sciences
|
Fanghui Zhao
|
Further Details
|
|
11487
|
GSK
|
A secondary Data-Analysis of Post-Traumatic Stress Disorder (PTSD) and Clinician-Administered PTSD Scale for DSM-5 (CAPS- 5)
|
Tunnell Government Services, Inc., Subcontractor to General Dynamics Information Technology (GDIT) working in support of US Army Medical Materiel Development Activity, Warfighter Brain Health (WBH) Project Management Office (PMO)
|
Elyse Katz, Ph.D.
|
Further Details
|
|
11504
|
GSK
|
Translating randomized controlled trial data to an external target population: a secondary analysis of data from the RV1 trial in South Africa and Malawi
|
University of North Carolina at Chapel Hill, Department of Epidemiology
|
Denise St. Jean
|
Further Details
|
|
11529
|
Sanofi
|
B cells and disease activity and anti-drug responses prior to and following alemtuzumab infusion for multiple sclerosis
|
Blizard Institute Barts and the London School of Medicine Queen Mary University of London
|
David Baker
|
Further Details
|
|
11560
|
GSK
|
Emotional blunting by mechanism of second-generation antidepressants: comparing bupropion and serotonin reuptake inhibitors
|
University of Saskatchewan, Department of Psychiatry
|
Dr. Evyn Peters
|
Further Details
|
|
11627
|
GSK
|
Validation of the diabetes Chronic Kidney Disease (CKD) and Heart Failure (HF) model in the HARMONY Outcomes trial
|
Tulane University School of Public Health and Tropical Medicine
|
Lizheng Shi
|
Further Details
|
Just a moment, the page is loading...